http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-100502947-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2004-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-100502947-C |
| titleOfInvention | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
| abstract | The invention provides a pharmaceutical product or kit comprising a first active ingredient which is a P2X7 receptor antagonist which P2X7 receptor antagonist is an adamantyl derivative and a second active ingredient which is a tumour necrosis factor alpha (TNFalpha) inhibitor, for use in the treatment of inflammatory disorders. |
| priorityDate | 2003-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 579.